ArticlePediatric nephrology (Berlin, Germany)2017
Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
Article in Pediatric nephrology (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Management and outcomes in children with lupus nephritis in the developing countries.Pediatric nephrology (Berlin, Germany) · 2023Pooled it
- Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Paediatric lupus nephritis: defining remission and the evolving therapeutic landscape.Pediatric nephrology (Berlin, Germany) · 2026Article
- Clinical presentations, treatments, and outcomes of pediatric lupus nephritis: a prospective cohort study from the Pediatric Nephrology Research Consortium.Pediatric nephrology (Berlin, Germany) · 2026Article
- The unique challenges of childhood-onset systemic lupus erythematosus and lupus nephritis patients: a proposed framework for an individualized transitional care plan.Pediatric nephrology (Berlin, Germany) · 2025Review
- Early-onset lupus nephritis.Clinical kidney journal · 2024Review
- BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months case-control study.World journal of clinical pediatrics · 2024Article
- Managing Lupus Nephritis in Children and Adolescents.Paediatric drugs · 2024Review
- Rituximab as an effective add-on maintenance therapy for disease activities in childhood-onset systemic lupus erythematosus.Lupus science & medicine · 2024Article
- Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2023Article
- Novel Therapeutics for Management of Lupus Nephritis: What Is Next?Kidney medicine · 2023Article
- Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study.Biomedicines · 2023Article
- Glucocorticoid discontinuation in pediatric-onset systemic lupus erythematosus: a single-center experience.Pediatric nephrology (Berlin, Germany) · 2022Article
- Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2022Article
- What Have We Learnt About the Treatment of Juvenile-Onset Systemic Lupus Erythematous Since Development of the SHARE Recommendations 2012?Frontiers in pediatrics · 2022Review
- Use of rituximab in paediatric nephrology.Archives of disease in childhood · 2021Review
- Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE.Pediatric rheumatology online journal · 2021Article
- Efficacy of a sequential treatment by belimumab in monogenic systemic lupus erythematosus.European journal of rheumatology · 2020Review
- An Update on the Diagnosis and Management of Lupus Nephritis.Current rheumatology reports · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildhood-onset lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). Despite treatment-related toxicities, cyclophosphamide (CYC) and glucocorticoid-based treatment protocols are still considered standard therapy in managing this multisystem disorder. An effective and safe alternative induction regimen is needed.
methodsForty-four pediatric patients with active LN aged 3.5-13.8 (median 8.4) years, of whom 32 entered the study at diagnosis of SLE, were followed over 36 months. Induction therapy consisted of methylprednisolone pulses followed by either rituximab (RTX) (n = 17), mycophenolate mofetil (MMF) (n = 12) or pulse-CYC (n = 15), with tapering dose of prednisolone orally. MMF was added as maintenance immunosuppressant (800 mg/m
resultsFlare-free survival was significantly higher at 36 months with RTX compared with MMF and CYC (100% for RTX vs. 83% for MMF. and 53% for CYC, p = 0·006). Twelve patients (76.5%) achieved complete remission with RTX compared with five (41.7%) and seven (46.7%) with MMF and CYC, respectively, at last follow-up. Requirement of mean daily dosage of prednisone was significantly lower in RTX group [p = 0.005 (RTX vs MMF); 0.0001 (RTX vs CYC) at 36 months] compared with other groups after the 3-month follow-up. In comparison with few minor adverse events in the other two cohorts, several serious adverse events occurred in the CYC group.
conclusionsEfficacy and medium-term safety of RTX induction followed by MMF maintenance therapy in inducing and maintaining remission among children with LN were evident in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.